Safety and Efficacy of DYNE-251 in Males with DMD Mutations Amenable to Exon 51 Skipping (S31.010)
Perry B. Shieh(Boston Children's Hospital), Michela Guglieri(Muscular Dystrophy UK), A. Dugar(Sarepta Therapeutics (United States)), Liesbeth De Waele(KU Leuven), Chris Mix, Kevin M. Flanigan(Nationwide Children's Hospital), Michelle Lorentzos(Children's Hospital at Westmead), Douglas S. Kerr(Vyne Therapeutics (United States)), Craig Campbell(London Health Sciences Centre), H. Phan(Rare Disease Therapeutics (United States)), Maria L. Naylor(Vyne Therapeutics (United States)), Nicolas Deconink, Soma Ray(Vyne Therapeutics (United States))
Cited by 0
Related Papers
Evidence‐based path to newborn screening for duchenne muscular dystrophy
|Annals of Neurology|2012|816
Eteplirsen for the treatment of Duchenne muscular dystrophy
|Annals of Neurology|2013|793
Distinctive patterns of microRNA expression in primary muscular disorders
|Proceedings of the National Academy of Sciences|2007|509
A phase I/IItrial of MYO‐029 in adult subjects with muscular dystrophy
|Annals of Neurology|2008|466